Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168, Rome, Italy.
Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168, Rome, Italy.
Crit Rev Oncol Hematol. 2021 Dec;168:103542. doi: 10.1016/j.critrevonc.2021.103542. Epub 2021 Nov 18.
Ovarian cancer (OC) is the most lethal gynecological malignancy and very little is known about the underlying tumorigenesis mechanisms. For other tumors, like colorectal cancer, a relationship between several opportunistic pathogens and cancer development and progression has been proven. Recent researches also underline a possible correlation between gut microbiota dysbiosis and cancer treatment efficacy and adverse effects. Several studies have also demonstrated a link between abdominal surgery and gut microbiota modifications. In this paper, we aim to review the available evidences of this issue in OC to understand if there is a relationship between gut microbiota modifications and efficacy and adverse effects of cancer therapies, either surgical and medical treatments. Well-designed clinical studies, with a robust translational component, are required to better understand the modulation of gut microbiota during OC treatment. The microbiota/microbiome composition analysis, in the near future, could represent a novel instrument to personalize anticancer therapies.
卵巢癌 (OC) 是最致命的妇科恶性肿瘤，其潜在的肿瘤发生机制知之甚少。对于其他肿瘤，如结直肠癌，已经证明几种机会性病原体与癌症的发生和发展之间存在关联。最近的研究还强调了肠道微生物失调与癌症治疗效果和不良反应之间可能存在相关性。几项研究还表明腹部手术与肠道微生物群的改变之间存在联系。在本文中，我们旨在综述 OC 中这一问题的现有证据，以了解肠道微生物群的改变是否与癌症治疗的疗效和不良反应（包括手术和药物治疗）之间存在关系。需要设计良好的临床研究，并具有强大的转化部分，以更好地了解 OC 治疗过程中肠道微生物群的调节。在不久的将来，微生物组/微生物群组成分析可能成为个性化抗癌治疗的新工具。
